Compare PRGO & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGO | PGEN |
|---|---|---|
| Founded | 1887 | 1998 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2013 | 2013 |
| Metric | PRGO | PGEN |
|---|---|---|
| Price | $10.78 | $3.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $19.33 | $7.67 |
| AVG Volume (30 Days) | 2.8M | ★ 4.7M |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 10.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $800,000.00 | ★ $230,981,000.00 |
| Revenue This Year | $0.02 | $342.78 |
| Revenue Next Year | $1.36 | $478.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.13 | $1.11 |
| 52 Week High | $29.08 | $5.47 |
| Indicator | PRGO | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 22.11 | 32.12 |
| Support Level | N/A | $2.99 |
| Resistance Level | $15.08 | $5.10 |
| Average True Range (ATR) | 0.60 | 0.32 |
| MACD | -0.41 | -0.12 |
| Stochastic Oscillator | 2.84 | 3.34 |
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.